Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease

References

• American Diabetes Association, 2014. Diagnosis and classification of diabetes mellitus. Diabetes care, 37(Suppl. 1), S81–S90.
   PubMed Web of Science ®Google Scholar
• Bittner, V., et al., 2009. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). American heart journal, 157, 548–555.
   PubMed Web of Science ®Google Scholar
• Camps, J., Marsillach, J., and Joven, J., 2009. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World journal of gastroenterology, 15, 1929–1933.
   PubMed Web of Science ®Google Scholar
• Choe, Y.G., et al., 2013. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. Journal of gastroenterology and hepatology, 28, 678–683.
   PubMed Web of Science ®Google Scholar
• Dowman, J.K., Tomlinson, J., and Newsome, P., 2010. Pathogenesis of non-alcoholic fatty liver disease. QJM: monthly journal of the association of physicians, 103, 71–83.
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson, K., et al., 2014. The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Obesity research & clinical practice, 106, 136–144.
   PubMed Web of Science ®Google Scholar
• Emamgholipour, S., et al., 2015. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetology & metabolic syndrome, 7, 108.
   PubMed Web of Science ®Google Scholar
• Eren, E., et al., 2014. Serum paraoxonase/arylesterase activity and oxidative stress status in children with metabolic syndrome. Journal of clinical research in pediatric endocrinology, 6, 163–168.
   PubMed Web of Science ®Google Scholar
• Hashemi, M., et al., 2012. Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease. Pathophysiology, 19, 115–119.
   PubMedGoogle Scholar
• Husain, K., et al., 2015. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World journal of biological chemistry, 6, 209–217.
   PubMedGoogle Scholar
• Jiang, Z.G., Robson, S.C., and Yao, Z., 2013. Lipoprotein metabolism in nonalcoholic fatty liver disease. Journal of biomedical research, 27, 1–13.
   PubMedGoogle Scholar
• Kelishadi, R., et al., 2009. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis, 204, 538–543.
   PubMed Web of Science ®Google Scholar
• Kota, S.K., et al., 2013. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian journal of endocrinology and metabolism, 17, 402–412.
   PubMedGoogle Scholar
• Lee, M.J., et al., 2017. The atherogenic index of plasma and the risk of mortality in incident dialysis patients: results from a nationwide prospective cohort in Korea. PLoS One, 12, e0177499.
   PubMed Web of Science ®Google Scholar
• Litvinov, D., Mahini, H., and Garelnabi, M., 2012. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. North American journal of medical sciences, 4, 523–532.
   PubMedGoogle Scholar
• Lonardo, A., et al., 2013. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Current pharmaceutical design, 19, 5177–5192.
   PubMed Web of Science ®Google Scholar
• Mahmoudi, M., et al., 2017. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. International journal of rheumatic diseases, 20, 287–297.
   PubMed Web of Science ®Google Scholar
• Merat, S., et al., 2015. PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (polyIran - liver) - study protocol. Archives of Iranian medicine, 18, 515–523.
   PubMed Web of Science ®Google Scholar
• Ng, C.J., et al., 2005. The paraoxonase gene family and atherosclerosis. Free radical biology & medicine, 38, 153–163.
   PubMed Web of Science ®Google Scholar
• Pirgon, O., et al., 2013. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. Journal of clinical research in pediatric endocrinology, 5, 33–39.
   PubMed Web of Science ®Google Scholar
• Rozenberg, O., et al., 2003. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free radical biology & medicine, 34, 774–784.
   PubMed Web of Science ®Google Scholar
• Samy, W. and Hassanian, M.A., 2011. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab journal of gastroenterology, 12, 80–85.
   PubMedGoogle Scholar
• Shanaki, M., et al., 2016. The circulating CTRP13 in type 2 diabetes and non-alcoholic fatty liver patients. PLoS One, 11, e0168082.
   PubMed Web of Science ®Google Scholar
• Sirimarco, G., et al., 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke, 45, 1429–1436.
   PubMed Web of Science ®Google Scholar
• Tamang, H.K., et al., 2014. Apo B/apo A-I ratio is statistically a better predictor of cardiovascular disease (CVD) than conventional lipid profile: a study from Kathmandu valley, Nepal. Journal of clinical and diagnostic research: JCDR, 8, 34–36.
   PubMedGoogle Scholar
• Torun, E., et al., 2014. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. Journal of pediatric endocrinology and metabolism, 27, 667–675.
   PubMed Web of Science ®Google Scholar
• Turak, O., et al., 2016. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict new cardiovascular events in essential hypertensive patients. The journal of clinical hypertension, 18, 772–777.
   Web of Science ®Google Scholar
• Walldius, G. and Jungner, I., 2004. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of internal medicine, 255, 188–205.
   PubMed Web of Science ®Google Scholar
• Walldius, G. and Jungner, I., 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy–a review of the evidence. Journal of internal medicine, 259, 493–519.
   PubMed Web of Science ®Google Scholar
• Younossi, Z.M., et al., 2016. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64, 73–84.
   PubMed Web of Science ®Google Scholar
• Yu, X.H., et al., 2013. Foam cells in atherosclerosis. Clinica chimica acta: international journal of clinical chemistry, 424, 245–252.
   PubMed Web of Science ®Google Scholar